Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1

被引：0
|
作者：
Tyring, S. [1 ]
Spelman, L. [2 ,3 ]
Igarashi, A. [4 ]
Ohtsuki, M. [5 ]
Li, Q. [6 ]
Mendelsohn, A. [7 ]
Parno, J. [7 ]
Guenthner, S. [8 ]
机构：
[1] Univ Texas Houston, Dept Dermatol, UTHlth, Houston, TX USA
[2] Verac Clin Res, Brisbane, Qld, Australia
[3] Prob Med Res, Waterloo, ON, Canada
[4] NNT Med Ctr Tokyo, Tokyo, Japan
[5] Jichi Med Univ Hosp, Shimotsuke, Tochigi, Japan
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[8] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [41] Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
    Thaci, Diamant
    Puig, Luis
    Merola, Joseph F.
    Jullien, Denis
    Costanzo, Antonio
    Wang, Maggie
    Deherder, Delphine
    Lopez Pinto, Jose M.
    Lebwohl, Mark
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4733 - 4735
  • [42] Long-term safety of ustekinumab in paediatric patients with moderate-to-severe plaque psoriasis: results from an ongoing observational study
    Mahe, Emmanuel
    Geldhof, Anja
    Movshovich, Evgenia
    Schreiber, Joerg
    Malynn, Sandra
    Efficace, Michela
    Seyger, Marieke M. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (03) : E43 - E43
  • [43] Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Iversen, Lars
    Peserico, Andrea
    Pau-Charles, Ignasi
    Blauvelt, Andrew
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB119 - AB119
  • [44] Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis
    van de Kerkhof, PCM
    Berth-Jones, J
    Griffiths, CEM
    Harrison, PV
    Hönigsmann, H
    Marks, R
    Roelandts, R
    Schöpf, E
    Trompke, C
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (03) : 414 - 422
  • [45] Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program
    Warren, Richard
    Sofen, Howard
    Imafuku, Shinichi
    Szepietowski, Jacek C.
    Blauvelt, Andrew
    Spelman, Lynda
    Toms, Jessica
    Buck, Alex
    Banerjee, Subhashis
    Menter, Alan
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4230 - 4232
  • [46] Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
    Spelman, Lynda
    Warren, Richard B.
    Sofen, Howard
    Imafuku, Shinichi
    Blauvelt, Andrew
    Toms, Jessica
    Buck, Alex
    Banerjee, Subhashis
    Menter, Alan
    Szepietowski, Jacek C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 28
  • [47] DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
    Warren, R. B.
    Sofen, H.
    Imafuku, S.
    Szepietowski, J.
    Blauvelt, A.
    Spelman, L.
    Colston, E.
    Toms, J.
    Buck, A.
    Banerjee, S.
    Menter, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 841 - 841
  • [48] Efficacy of long-term tildrakizumab for plaque psoriasis: PASI 50/75/90/100 and PGA for up to 5 years of treatment in reSURFACE 2
    Roebuck, Heather
    Farberg, Aaron S.
    Hanna, Sameh
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB80 - AB80
  • [49] Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial
    Gottlieb, AB
    Hamilton, T
    Caro, I
    Kwon, P
    Compton, PG
    Leonardi, CL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S154 - S163
  • [50] Safety and efficacy of ustekinumab in adolescent patients with moderate to severe plaque psoriasis: Results through 1 year of the phase 3 CADMUS trial
    Landells, Ian
    Marano, Collen
    Hsu, Ming-Chun
    Li, Shu
    Eichenfield, Lawrence
    Hoeger, Peter
    Menter, Alan
    Paller, Amy
    Taieb, Alain
    Randazzo, Bruce
    Szapary, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB202 - AB202
12345